FDAnews
www.fdanews.com/articles/205158-us-government-pays-129-billion-for-more-doses-of-eli-lillys-covid-19-therapy

U.S. Government Pays $1.29 Billion for More Doses of Eli Lilly’s COVID-19 Therapy

November 3, 2021

The U.S. government has purchased a further 614,000 doses of Eli Lilly’s COVID-19 antibody cocktail, bamlanivimab with etesevimab, for $1.29 billion.

The deal stipulates that Lilly will supply a minimum of 400,000 doses by the end of this year, with all doses to be delivered by the end of January 2022.

The combination therapy is FDA-authorized for treatment of mild-to-moderate COVID-19 infections and for preventing postexposure infection for people at high risk of progressing to severe disease.

View today's stories